肿瘤细胞治疗研究
ALL SOURCES
Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-fr
这些发现为TILT-123联合TIL疗法提供了机制上的见解，并为未来的生物标志物导向临床研究提出了方向。
Radiotherapy Enhances the Oncolytic Efficacy of the Novel Oncolytic Herpesvirus VG161 and Amplifies Its Antitumor Immunity in Breast Cancer.
我们的研究结果表明，VG161与RT联合的最佳方案是在VG161感染后6小时给予5 Gy照射，这能确保RT最大程度地促进VG161在BC中的复制。
Recent Advances in Tumor-Infiltrating Lymphocyte Therapy for Melanoma.
黑色素瘤是侵袭性最强的皮肤癌形式，并且仍然是皮肤癌相关死亡率的主要原因。
Novel tumor-infiltrating lymphocytes therapy in solid tumors: latest updates from 2025 ASCO annual meeting.
TIL（肿瘤浸润淋巴细胞）疗法作为过继性细胞疗法（ACT）中极具前景的一种形式，已在治疗晚期黑色素瘤方面取得成功。
The trinity of T cell engagement: navigating the molecular and clinical landscape of CAR-T, TILs, and TCEs in the war against cancer.
癌症免疫疗法的出现从根本上重构了肿瘤学范式，从直接靶向肿瘤细胞动力学的药物转向赋能宿主免疫系统识别和清除恶性肿瘤的策略。
Oncolytic virotherapy at the tumor microenvironment-CAR Therapy interface: Mechanisms, clinical translation, and future directions.
溶瘤病毒疗法已从一种肿瘤选择性溶细胞策略演变为一种可编程的免疫治疗平台，能够重塑肿瘤微环境（TME）。
Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma.
在这项1期试验中，17例转移性检查点抑制剂耐药黑色素瘤患者接受了TILT-123和TIL治疗，未进行预处理化疗或后处理IL-2。
An armed oncolytic virus enhances the efficacy of tumor-infiltrating lymphocyte therapy by converting tumors to artificial antigen-presenting cells in
TIL（肿瘤浸润淋巴细胞）疗法的全部潜力一直受制于 TIL 活化不足、持久性低以及肿瘤新抗原呈递效率低下。
Anti-PD-1 single-chain variable fragments in cancer immunotherapy: from molecular engineering to clinical translation.
程序性死亡-1（PD-1）免疫检查点是癌症中T细胞耗竭和免疫逃逸的核心调节因子。
MEMBER ACCOUNT
登录成功会直接打开下一页。
